Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster

Bristol Myers Squibb’s deucravacitinib has hit its first bump in the road. After blowing Amgen’s Otezla away in psoriasis, deucravacitinib went into a phase 2 readout in ulcerative colitis flying high—only to fail to meet the primary or secondary endpoints.